ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMAB I MAB

1.84
-0.02 (-1.08%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
I MAB NASDAQ:IMAB NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.02 -1.08% 1.84 1.66 3.73 1.86 1.83 1.85 98,437 21:25:00

I-MAB Filed 2023 Annual Report on Form 20-F

30/04/2024 12:00pm

PR Newswire (US)


I MAB (NASDAQ:IMAB)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more I MAB Charts.

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

(PRNewsfoto/I-Mab Biopharma)

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@i-mabbiopharma.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html

SOURCE I-Mab Biopharma

Copyright 2024 PR Newswire

1 Year I MAB Chart

1 Year I MAB Chart

1 Month I MAB Chart

1 Month I MAB Chart

Your Recent History

Delayed Upgrade Clock